Spots Global Cancer Trial Database for Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
Official Title: A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer
Study ID: NCT05826275
Conditions
Study Description
Brief Summary: This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Neil J Clendeninn, MD, PhD
Affiliation: Chief Medical Officer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
